Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NK cell subsets define sustained remission in rheumatoid arthritis
Carl Coyle, … , Rowann Bowcutt, Esperanza Perucha
Carl Coyle, … , Rowann Bowcutt, Esperanza Perucha
Published October 17, 2024
Citation Information: JCI Insight. 2024;9(23):e182390. https://doi.org/10.1172/jci.insight.182390.
View: Text | PDF
Research Article

NK cell subsets define sustained remission in rheumatoid arthritis

  • Text
  • PDF
Abstract

Rheumatoid arthritis (RA) is an immune-mediated, chronic inflammatory condition. With modern therapeutics and evidence-based management strategies, achieving sustained remission is increasingly common. To prevent complications associated with prolonged use of immunosuppressants, drug tapering or withdrawal is recommended. However, due to the lack of tools that define immunological remission, disease flares are frequent, highlighting the need for a more precision medicine–based approach. Utilizing high-dimensional phenotyping platforms, we set out to define peripheral blood immunological signatures of sustained remission in RA. We identified that CD8+CD57+KIR2DL1+ NK cells are associated with sustained remission. Functional studies uncovered an NK cell subset characterized by normal degranulation responses and reduced proinflammatory cytokine expression, which was elevated in sustained remission. Furthermore, flow cytometric analysis of NK cells from synovial fluid combined with interrogation of a publicly available single-cell RNA-Seq dataset of synovial tissue from active RA identified a deficiency of the phenotypic characteristics associated with this NK cell remission signature. In summary, we have uncovered an immune signature of RA remission associated with compositional changes in NK cell phenotype and function that has implications for understanding the effect of sustained remission on host immunity and distinct features that may define operational tolerance in RA.

Authors

Carl Coyle, Margaret Ma, Yann Abraham, Christopher B. Mahony, Kathryn Steel, Catherine Simpson, Nadia Guerra, Adam P. Croft, Stephen Rapecki, Andrew Cope, Rowann Bowcutt, Esperanza Perucha

×

Figure 5

A distinct phenotypic subset of NK cells associated with in vitro polyfunctional responses is reduced in stable remission.

Options: View larger image (or click on image) Download as PowerPoint
A distinct phenotypic subset of NK cells associated with in vitro polyfu...
(A and B) The in vitro induction of a CD56dimCD16– NK cell population, which arises in response to IL-2 stimulation and K562 interaction, is reduced upon treatment with TAPI-0 (5 μM). (C) The proportion of CD56dimCD16– NK cells in response to IL-2 stimulation and K562 interaction. (D–H) Comparison of the proportion of NK cells expressing TNF-α, IFN-γ, and CD107a (D–F) as well as CD107a+IFN-γ+TNF-α+ (G) and CD107a+IFN-γ–TNF-α– (H) functional subsets between CD56dimCD16– and CD56dimCD16+ NK cells. (I) Representative flow plot demonstrating the expression of KIR2DL1 and NKG2A. (J and K) Differences in the expression from baseline (IL-2–K562–) of NKG2A, and KIR2DL1 between CD56dimCD16– and CD56dimCD16+ subsets. (L) Comparison of the proportion of CD57+ NK cells between CD56dimCD16– and CD56dimCD16+ subsets. Whiskers on plots represent minimum to maximum values. All P values were determined using the Kruskal-Wallis test with Dunn’s multiple-test correction. *P < 0.05, **P < 0.01, ****P < 0.0001

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts